Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow

Study Overview
=================
Brief Summary
-----------------
Infants with congenital heart disease and increased pulmonary blood flow have altered carnitine homeostasis that is associated with clinical outcomes; and L-carnitine treatment will attenuate these alterations and improve clinical outcomes. The investigators will pilot a trial assessing the safety and pharmacokinetics of perioperative IV L-carnitine administration in these patients. To this end, a pilot clinical trial is proposed. Infants with ventricular septal defects or atrioventricular septal defects undergoing complete surgical repair will receive L-carnitine (25, 50, or 100 mg/kg, IV) just prior to cardiopulmonary bypass (CPB) and 2hr after CPB. Carnitine levels will be measured before CPB, and before and 0.5, 1.5, 3, 5, 9, 12, and 24h after the second dose. The safety, pharmacokinetic profile, feasibility, and effect of L-carnitine administration on biochemical parameters, as well as clinical outcomes will be determined. The investigators expect this pilot to provide the data needed to proceed with a placebo-based randomized, controlled, trial.

Detailed Description
-----------------
AIM: To pilot a trial assessing the safety and pharmacokinetics (PK) of perioperative IV L-carnitine administration in these patients. To this end, a pilot clinical trial is proposed. Infants with VSD or AVSD undergoing complete repair will receive L-carnitine, in one of 3 doses (25, 50, or 100 mg/kg, IV), just prior to CPB, and again 2 hr after CPB. Serial blood samples will be obtained to determine free, total, and acylcarnitine levels, and plasma markers of mitochondrial function, oxidative stress, and bioavailable NO. Adverse events will be sought, and clinical outcomes will be assessed. Study design: The inclusion and exclusion criteria are as described in Aim 3A except only infants with VSD or AVSD will be enrolled (no TOF). The safety profile of L-carnitine is outstanding, with no reports of toxicity from overdose reported113. In fact, the only adverse reactions reported are transient nausea and vomiting, and less commonly gastritis. However, although rare, seizures have been reported to occur in patients receiving L-carnitine. Therefore, the major adverse events that will be monitored include evidence of seizure activity and GI bleeding. As per routine, any patient suspected of having seizures is monitored with continuous EEG. Dosing is not well studied in children, particularly critically ill children67, 114-116117. In addition, the effect of CPB on L-carnitine clearance in children is not known. Therefore, a major goal of this sub-aim is to establish a pharmacokinetic profile of L-carnitine in this patient population undergoing surgery with CPB, in order to move forward with a larger randomized trial powered for efficacy in prevention of increased PVR post-bypass in at-risk infants. Plasma concentration profiles after IV bolus dosing in adults were described by a two-compartmental model67, 113, 114, 118. Usual pediatric dosing is not well delineated, but recommendations include a 50 mg/kg bolus followed by an infusion of 50mg/kg/day, that can be increased to 300 mg/kg/day113, 119. Therefore, we will begin at a lower dose (25 mg/kg), and escalate the dose after each group of 5. No intra-patient escalation will be allowed and the dose will not be escalated until all patients in the current dose level have been followed to hospital discharge or 30 days post-op and the safety and PK data have been analyzed. The DSMB will approve all dose escalations. The dosing goal will be to achieve normal or supra-normal free carnitine levels ( 50 μmol/L) and low AC levels ( 3 μmol/L) just before and for 24 hrs after CPB; the period with the greatest risk of pulmonary vascular morbidity.

Official Title
-----------------
Phase 1 Study of the Safety and Pharmacokinetics of Perioperative IV L-carnitine Administration in Patients With Congenital Heart Disease With Increased Pulmonary Blood Flow

Conditions
-----------------
Heart Septal Defects, Ventricular, Atrioventricular Septal Defect

Intervention / Treatment
-----------------
* Drug: IV L-carnitine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: have unrestrictive VSD, AVSD are undergoing complete repair are between 2-12 months of age are corrected gestational age ≥34 weeks will have an indwelling arterial or venous line have not had enteral or parenteral nutrition for at least 6 hrs Exclusion Criteria: have body weight < 2.0 kg pulmonary artery or vein abnormalities not being addressed surgically suspected or proven in-born error of metabolism have other major congenital abnormalities that affect the cardiopulmonary system are taking carnitine supplementation

Ages Eligible for Study
-----------------
Minimum Age: 2 Months
Maximum Age: 12 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IV L-carnitine<br>L-carnitine (25, 50, or 100mg/kg IV) will be given, 30-60 minutes prior to the initiation of CPB, and a second dose  2 hr. following separation from CPB (with a minimum of 4 hrs from initial dose). The first 5 subjects will receive 25 mg/kg, with an escalation of dose after each 5 subjects enrolled. The study drug will be brought to the operating room and administered over 5 minutes by the anesthesiologist after an IV has been placed. Prior to the administration of the study drug, and again 24 and 48 hrs after CPB, 3.0 ml of blood will be collected for determinations of carnitine levels (free, total, and acylcarnitine), mitochondrial function, ROS and bioavailable NO as described in Aim 3A. Additional blood (0.5-1.0 ml) will be obtained to determine carnitine levels before CPB, and then before and 0.5, 1.5, 3, 5, 9, 12, and 24h after the second dose. | Drug: IV L-carnitine<br>* See arm description<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood carnitine level (free, total, and acylcarnitine) |  | At enrollment (first dose), and again 24 and 48 hrs after enrollment. 2 hours after enrollment (at time of second dose) and 0.5, 1.5, 3, 5, 9, 12, and 24h after the second dose. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioavailable nitric oxide |  | At enrollment (first dose), and again 24 and 48 hrs after enrollment. | 
| Plasma levels of superoxide |  | At enrollment (first dose), and again 24 and 48 hrs after enrollment. | 
| Carnitine Palmityl Transporter-1 and -2 expression |  | At enrollment (first dose), and again 24 and 48 hrs after enrollment. | 
| Cardiopulmonary bypass |  | Participants will be followed for the duration of hospital stay, an expected average of 2 weeks | 
| Echocardiographic measurements | Estimates of PPA and right ventricular (RV) function by transesophageal ECHO (TEE) | Participants will be followed for the duration of hospital stay, an expected average of 2 weeks | 
| Blood BNP level |  | Daily during the hospitalization, estimated to be an average of 2 weeks | 
| Duration of mechanical ventilation |  | During hospitalization which is an average of 2 weeks | 
| Vasopressor infusions |  | Duration of hospitalization which is an average of 2 weeks | 
| Need for inhaled nitric oxide |  | During hospitalization (average of 2 weeks) | 
| Incidence of low cardiac output syndrome |  | Postoperative hospitalization (average of 2 weeks) | 
| Need for extracorporeal life support |  | During hospitalization (average of 2 weeks) | 
| Plasma H202 levels |  | At enrollment (first dose), and again 24 and 48 hrs after enrollment. | 
| Aortic cross clamp times |  | Participants will be followed for the duration of hospital stay, an expected average of 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
congenital heart disease, ventricular septal defect, atrioventricular septal defect, increased pulmonary blood flow, nitric oxide